The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Ethics Forum: The Ethical Pitfalls of Clinical Trials

Ethics Forum: The Ethical Pitfalls of Clinical Trials

April 6, 2012 • By Robert H. Shmerling, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The Case

Your patient is deciding whether to enroll in a clinical trial at your institution and wants your advice about whether to participate. The study compares two drugs for acute pain following minor outpatient surgery. One drug is a newly developed analgesic that may soon be approved by the U.S. Food and Drug Administration. The other is an older, generic drug that has been around for decades. The protocol randomly assigns study subjects to one of several doses of the novel medication or a fixed dose of the older analgesic.

You Might Also Like
  • Ethics Forum: The Ethical Challenges of Recruiting Patients for Clinical Trials
  • Ethics Forum: The Ethical Side of End-of-Life Decisions
  • Ethics Forum: Ethical Challenges Arise for Rheumatologists Pressed to See Patients of High Social, Professional Standing Before Others
Explore This Issue
April 2012
Also By This Author
  • Letter: There’s No Reason Now to Screen for Uric Acid

You are aware of review articles by pain experts describing how physicians commonly underdose the older drug. In fact, prior studies suggest that the “usual” or “standard” dose of the older drug—the one used in the study protocol—provides inadequate pain relief in nearly half of patients. That is why pain specialists carefully up-titrate the dose of this medication to achieve pain relief and routinely recommend that other clinicians do the same. The older drug’s package insert allows a wide range of doses; the study protocol’s fixed dose is at the lower end of this range.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

You recognize that your patient may have her pain undertreated if she’s assigned to receive the older drug.

Do you advise your patient to enroll? Do you see any ethical concerns about the design of this study?

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Discussion

This scenario raises an issue often faced by researchers designing a study to explore the effectiveness of a new therapy: What is the appropriate comparator? Although a placebo-controlled design represents the gold standard for clinical trials, assigning one group to receive a treatment expected to be ineffective is ethically problematic. Ideally, the control group should (at the very least) receive treatment considered to be the standard of care.

However, in the case described, the trial proposes a comparison group that receives a dose of pain medication known to undertreat pain in many patients. Even though the protocol employs a commonly used dose, the protocol does not allow optimal dosing. Thus, this protocol may be unethical because it assigns some patients to a suboptimal treatment regimen. In addition, the design may be biased toward the new drug because a range of doses of the new drug are being compared to a fixed, commonly ineffective dose of the older drug.

The counter-argument is that this study has a limited goal: to compare a new drug to a commonly prescribed dose of an old drug that would be considered by many clinicians to represent the standard of care. However, this justification raises ethical concerns as well.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

What Constitutes an Ethical Clinical Trial?

The policies and recommendations contained in the Nuremberg Code, the Belmont Report, and the International Ethical Guidelines for Biomedical Research Involving Human Subjects and related consensus guidelines represent significant progress in the evolution of ethical clinical trials.1-3 As institutional review boards are expected to take these well-established guidelines to heart, the question of ensuring an ethical trial may seem academic. However, when common or usual care is also suboptimal, deciding whether a study protocol is ethical may not be straightforward.

Pages: 1 2 3 4 | Single Page

Filed Under: Ethics, Professional Topics Tagged With: clinical trials, drug, Ethics, Methotrexate, Research, Rheumatoid arthritis, rheumatologistIssue: April 2012

You Might Also Like:
  • Ethics Forum: The Ethical Challenges of Recruiting Patients for Clinical Trials
  • Ethics Forum: The Ethical Side of End-of-Life Decisions
  • Ethics Forum: Ethical Challenges Arise for Rheumatologists Pressed to See Patients of High Social, Professional Standing Before Others
  • Ethics Forum: Prescribing Teratogenic Medications to Adolescents Can Raise Confidentiality, Ethical Concerns

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)